Oncology ImagingArchives
Baseline whole-body metabolic tumor volume as an independent prognostic marker in diffuse large B-cell lymphoma: a PET/cT-based study
Oncology Imaging 1 min.
Oncology Imaging
1 min.
Published on 28/07/2026 |
Original article (Full-text)
| Sahiyyaddin
Aghazada
et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2701956
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes despite standard treatments. This study aimed to evaluate the prognostic significance of whole-body metabolic tumor volume and total lesion glycolysis (WB-MTV, WB-TLG) obtained from positron emission tomography/computed...
Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223
Oncology Imaging 1 min.
Oncology Imaging
1 min.
Published on 21/07/2026 |
Original article (Full-text)
| Fukushima, Yoshimitsu et al. | European Journal of Hybrid Imaging. Volume 10(1).
Metastatic castration-resistant prostate cancer (mCRPC) is bone-predominant, requiring imaging biomarkers to guide Ra-223 therapy. We evaluated overall metabolic bone volume (OMBV) and overall total bone uptake (OTBU) from bone SPECT/CT as prognostic markers in mCRPC patients treated with Ra-223. Methods:...
